Adjunct to diet & exercise to improve glycemic control in adult patients w/ type 2 DM for whom metformin is inappropriate due to contraindications or intolerance. Combination w/ metformin or sulfonylurea in adult patients w/ type 2 DM when diet & exercise + monotherapy w/ 1 of these agents does not provide adequate glycemic control. Combination w/ metformin & either sulfonylurea or pioglitazone in adult patients w/ type 2 DM when diet, exercise & dual therapy (w/ metformin + either sulfonylurea or pioglitazone) do not provide adequate glycemic control. Add-on combination therapy w/ insulin (w/ or w/o metformin) in adult patients w/ type 2 DM when diet & exercise & therapy w/ insulin (w/ or w/o metformin) do not provide adequate glycemic control. Adjunct to diet, exercise & standard of card therapy to reduce risk of major adverse CV events in adult patients w/ type 2 DM & established CV disease. Adjunct to diet, exercise & standard of care therapy to reduce risk of end-stage kidney disease, doubling of serum creatinine & CV death in adult patients w/ type 2 DM & diabetic nephropathy w/ albuminuria (>33.9 mg/mmol).
Discontinue use if Fournier's gangrene is suspected. Not recommended for use in patients w/ type 1 diabetes. Not to be used for treatment of diabetic ketoacidosis. Patients at risk for AR related to vol depletion; patients w/ already elevated haematocrit; patient history increasing risk for amputation. History of genital mycotic infections. Complicated UTI; NYHA class III cardiac failure. Not to be taken by patients w/ galactose intolerance, total lactase deficiency or glucose-galactose malabsorption. May affect ability to drive & use machines. Moderate renal impairment. Not to be used during pregnancy & lactation. Elderly ≥65 yr.
Sign Out
